MedTrace Logo

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

NCT02232087 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-06-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the body's response to several doses of two different inhalation products in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Salmeterol

A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

DRUG

fluticasone propionate

A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Sponsors & Collaborators

  • Kindeva Drug Delivery

    lead INDUSTRY

Principal Investigators

  • Pui Leung, MD · Quotient Clinical Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02232087 on ClinicalTrials.gov